Original Articles
The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease,☆☆

https://doi.org/10.1067/mpd.2001.112171Get rights and content

Abstract

Objective: To assess the long-term systemic and neurologic responses to enzyme replacement therapy (ERT) with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease. Study design: Patients with type 3 Gaucher’s disease (n = 21), aged 8 months to 35 years, were enrolled in a prospective study. Enzyme dose was adjusted to control systemic manifestations. Clinical and laboratory evaluations were performed at baseline and every 6 to 12 months thereafter. Patients were followed up for 2 to 8 years. Results: Significant improvement in hemoglobin levels, platelet count, and acid phosphatase values occurred. Liver and spleen volume markedly decreased, and bone structure improved. Nineteen patients had asymptomatic interstitial lung disease unresponsive to ERT. Supranuclear gaze palsy remained stable in 19 patients, worsened in one patient, and improved in one. Cognitive function remained unchanged or improved over time in 13 patients but decreased in 8 patients, 3 of whom developed progressive myoclonic encephalopathy accompanied by cranial magnetic resonance imaging and electroencephalographic deterioration. Conclusions: At relatively high doses, ERT reverses almost all the systemic manifestations in patients with type 3 Gaucher’s disease. Most treated patients do not deteriorate neurologically. Novel therapeutic strategies are required to reverse the pulmonary and neuronopathic aspects of the disease. (J Pediatr 2001;138:539-47)

Section snippets

Patients

Twenty-one patients (12 males and 9 females), ranging in age from 8 months to 35 years, with neuronopathic Gaucher’s disease were evaluated (Table I).At the time of enrollment, 3 patients were adults (age range, 18-30 years) and 18 were children (age range, 8 months-15 years). Seven patients underwent partial or complete splenectomy before enrollment, and one patient had a partial splenectomy during the follow-up period. Four patients were receiving ERT when they entered the study. The length

Enzyme Doses

The enzyme doses ranged between 120 IU/kg and 480 IU/kg of body weight/4 wk; 18 patients received biweekly doses of 60 IU/kg. Patient 3 responded only to 120 IU/kg/2 wk; patient 9 received 60 IU to 120 IU/kg/wk in an attempt to induce tolerance to the enzyme after development of neutralizing antibodies.32 Initially, patient 11 did not respond to an enzyme dose of 120 IU/kg/wk but did respond after a partial splenectomy (see below). Currently, all but 3 patients receive 60 IU/kg every 2 weeks.

Discussion

ERT is safe and effective in reversing most of the systemic manifestations of chronic neuronopathic (type 3) Gaucher’s disease in a large cohort of patients. The treatment rapidly reduced organomegaly and corrected hematologic abnormalities. ERT improved femoral cortical bone thickness and normalized the bone marrow signal on T1-weighted MRI images. Although cortical bone thickness was determined only in the femur and does not necessarily reflect other skeletal regions, this finding documented

Acknowledgements

We thank the patients and their families for their participation, Dr Thierry Billette de Villemeur for referral of patients, and Devera G. Schoenberg, MS, for editorial assistance.

References (37)

  • R Schiffmann et al.

    Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease

    Ann Neurol

    (1997)
  • MC Patterson et al.

    Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease

    Neurology

    (1993)
  • A Erikson et al.

    Neuronopathic forms of Gaucher disease

  • JM Henderson et al.

    Gaucher’s disease complicated by bleeding esophageal varices and colonic infiltration by Gaucher cells

    Am J Gastroenterol

    (1991)
  • JEL Sales et al.

    Gaucher’s disease and portal hypertension

    Br J Surg

    (1979)
  • ND Theise et al.

    Pulmonary hypertension and Gaucher’s disease: logical association or mere coincidence?

    Am J Pediatr Hematol Oncol

    (1990)
  • Y Morimura et al.

    Gaucher disease type I (adult type), with massive involvement of the kidneys and lungs

    Virchows Arch

    (1994)
  • NW Barton et al.

    Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease

    N Engl J Med

    (1991)
  • Cited by (148)

    • Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders

      2022, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Although ERT is effective in reversing hepatosplenomegaly and hematologic manifestations, limitations were identified from these early studies, including insufficient reversal of pathologies in organs such as muscle, bone, cartilage, heart and lungs. Unfortunately, ERTs offer marginal benefits in cases where there are neurological complications – this may result from the inability of replacement enzymes to cross the blood–brain barrier (BBB) [38–40]. Moreover, host antibodies recognize infused (recombinant) enzyme molecules and result in their rapid removal from serum.

    • Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

      2021, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      Therefore, the enhancement of GCase activity may be also applied in the treatment of PD. However, since GCase cannot transverse the blood−brain barrier, the direct application of enzyme replacement therapy is ineffective for PD155. Later, it was proposed to develop small-molecule drug chaperones which could be used as an alternative therapy for PD156,157.

    View all citing articles on Scopus

    *Collaborators: Tappas K. Bannarjee, MD, K. Crutchfield, MD, Karen Frei, MD, Mary-Ann McKee, MD, David F. Moore, MD, PhD, DIC, and Ann Tournay, MD

    ☆☆

    Reprint requests: Raphael Schiffmann, MD, National Institutes of Health, Building 10, Room 3D03, 9000 Rockville Pike, Bethesda, MD 20892-1260.

    View full text